• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » NxStage Medical’s Todd Snell talks FDA, Brexit & regulatory strategy

NxStage Medical’s Todd Snell talks FDA, Brexit & regulatory strategy

August 25, 2017 By Sarah Faulkner

Fresenius Medical Care acquires NxStage MedicalBetween the consequences of Brexit and a new commissioner at the FDA, executives across medtech are bracing for change within the global regulatory landscape. NxStage Medical‘s (NSDQ:NXTM) SVP of quality assurance, regulatory & clinical affairs, Todd Snell, spoke with MassDevice.com editor Sarah Faulkner about what he’s observing from his post at the Lawrence, Mass.-based company.

Faulkner: What has caught your eye from Scott Gottlieb’s first moves as head of the FDA?

Snell: I’m finding that there’s a real speed to FDA establishing alternative pathways for regulating software. In the past two weeks, FDA announced a program where companies can be part of a pilot where, if their inspection history and submission history is strong, the FDA may ‘pre-certify’ companies.

The intent here is to de-risk certain types of medical device software and hopefully provide a less burdensome pathway. I feel that’s a positive step out of the gate.

Faulkner: What are you keeping an eye on in the coming year in terms of regulatory policy?

Snell

Snell: One of my top priorities is to understand and plan for the European Medical Device Regulations along with Brexit. I’m very concerned that the number of Notified Bodies will start to decrease due to their increased legal responsibilities for the medical devices manufactured by their clients.

As the Notified Body pool potentially decreases I’m concerned that there will be difficulty in transitioning to the few Notified Bodies still operating in the future. On the other hand I believe it’s going to become more transparent and easier in the future to collaborate with FDA [compared to the European Union].

Faulkner: What are some best practices that companies should line themselves up for regulatory success?

Snell: I think it’s really about preparing for the clinical evidence required in the EU for existing products on the market and new product approvals.

We have already begun focusing on improving our clinical evaluations for the EU, which weren’t as heavily scrutinized in the past.

From a regulatory-clinical perspective, the increased scrutiny of clinical evidence in the EU may become the most costly and highest risk area for medical device manufacturers.

The need for a solid clinical strategy is critical going forward. We do very proactive post-market risk reviews of our products annually and look extensively into our clinical evidence and post-market experience and ask, “is the product doing what we intended it to do?”, “does our risk profile need to be updated?, and “is our clinical evidence sufficient?”

See Snell and other leading minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Food & Drug Administration (FDA), Regulatory/Compliance, Wall Street Beat Tagged With: NxStage Medical Inc.

More recent news

  • Neuralink files to raise $649M in new equity offering
  • BofA: Surgical robot remanufacturing not a major setback for Intuitive
  • InspireMD wins CE Mark approval for CGuard Prime
  • Philips reports first cases for VeriSight Pro 3D ICE catheter in Europe
  • Ceryx Medical raises $15M to support bioelectronic pacemaker

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy